introduction
Although endocrine therapy is commonly used to treat hormone receptor-positive advanced breast cancer (ABC), patients with human epidermal growth factor receptor 2 (HER2)-positive disease are generally less responsive to such treatments. Overexpression of the HER2 receptor has been linked with resistance to selective estrogen receptor (ER)-modifying agents (SERMs) such as tamoxifen [1] [2] [3] [4] [5] [6] [7] [8] [9] .
Fulvestrant (Faslodexä), a novel ER antagonist with no agonist effects, is licensed for the treatment of postmenopausal women with ABC after recurrence or progression on prior antiestrogen therapy [10] . It is also effective following nonsteroidal aromatase inhibitor (AI) failure [11] . Fulvestrant has a distinct mode of action from other endocrine agents acting on the ER [12] . Therefore, it is possible that HER2 overexpression may have a different impact upon the activity of fulvestrant compared with tamoxifen or other SERMs [13] . Indeed, preclinical data show that fulvestrant retains activity in tamoxifen-resistant [14] and also in raloxifene-resistant tumours that overexpress HER2 [15] . Clinical data, based on small subsets of patients, have also indicated that fulvestrant has activity in patients with ER-positive/HER2-positive tumours [16] [17] [18] [19] .
Fulvestrant exhibits a high ER-binding affinity and produces complete receptor blockade ( Figure 1 ). Therefore, fulvestrant has no estrogen agonist activity and is associated with reduced risk of the endometrial abnormalities seen with tamoxifen [20] [21] [22] [23] . Equally important, following fulvestrant binding to the ER, dimerisation is impaired and the bound receptor is rapidly degraded, a process unique to fulvestrant among antiestrogens. It has been shown that ER-mediated signalling can interact with the epidermal growth factor receptor (EGFR)/ HER2-mediated pathways [6] [7] [8] 24] growth stimulus for breast tumours. Degradation of ER by fulvestrant may limit the potential for such cross-talk and delay the time to development of resistance to endocrine therapy. HER2 is overexpressed in only 20%-30% of breast cancer patients [25] , making the HER2-positive subgroup of patients in endocrine therapy trials relatively small. To more fully assess the activity of fulvestrant in patients with HER2-positive disease, we have pooled data from centres treating patients with HER2-positive ABC with fulvestrant in clinical practice.
methods study design
This was a retrospective analysis of data from patients with HER2-positive ABC who had been treated with fulvestrant in several cancer centres across the world. All centres approached were included in the analysis if they supplied data on all known patients with HER2-positive and hormone receptor-positive ABC treated with fulvestrant at their centre. Therefore, this study did not selectively exclude data or centres from the analysis.
patients and assessments
Only data from postmenopausal women with HER2-positive ABC progressing at the start of treatment were pooled from 10 centres in Europe, Israel, Brazil and Canada. Patients were classed as having HER2-positive disease if they scored 3+ on the HercepTestä (Dako A/S, Glostrup, Denmark) or the SP3 rabbit monoclonal antibody test [26, 27] (Epitomics, Burlingame, CA), or if they had a score of 2+ subsequently confirmed by fluorescence in situ hybridisation. Hormone receptor status [ER and progesterone receptor (PgR)] was classified as positive or negative, according to local immunohistochemical assessment in each participating centre, or unknown (when no assessment had been made).
The data collected from patient records included age, dates of treatment, number and types of previous therapies, response to fulvestrant and current status. Sites of metastases were noted (visceral sites: lung, liver, stomach, intestine; non-visceral sites; or both). Adverse events (AEs) during the treatment period were recorded. Nevertheless, since this was a post hoc analysis using data from a number of treatment centres, there was variability in the collection and completeness of tolerability data.
treatment and response to treatment
Fulvestrant was administered as a monthly i.m. injection (250 mg every 28 6 3 days) until disease progression or discontinuation for other reasons. Clinical response was assessed using RECIST or International Union Against Cancer criteria, or the clinical judgement of the treating physician, according to each centre's protocols. Responses were classified as complete response (CR), partial response (PR), stable disease (SD) lasting ‡6 months or disease progression. All patients who received fulvestrant for ‡6 months 
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were considered to have achieved SD, in the absence of information to the contrary. Clinical benefit (CB) was defined as the proportion of patients experiencing a response (CR or PR) or SD lasting ‡6 months. Fulvestrant activity was analysed by sites of metastases, hormone receptor status and prior breast cancer treatments. Any patient who received a prior endocrine therapy for >6 months was categorised as having CB, unless specifically recorded otherwise. results demography and baseline disease characteristics Data were collected and pooled from 102 patients with HER2-positive ABC who received fulvestrant treatment; five of these patients also received concurrent trastuzumab treatment. Patients (n) were recruited from Italy (21), Austria (20) , Belgium (18), Germany (11), Canada (10), the Czech Republic (6), Israel (6), Brazil (6) and the UK (4). At initiation of fulvestrant treatment, patients were a median age of 60 years, and had received a median of 1.5 prior endocrine and 1.8 chemotherapies for ABC (Table 1) . Median duration of fulvestrant treatment was 8.1 months (range . At the time of data collection, six patients were still receiving fulvestrant treatment (one with concurrent trastuzumab).
ER and/or PgR status was known in 101 patients (Table 1) . Most patients were ER positive (n = 94). Fifty-seven (55.9%) were also PgR positive. The majority (n = 63, 61.8%) had visceral metastases, and one-third (n = 35, 34.3%) had metastases at ‡3 sites when treatment was initiated (Table 1) .
At first diagnosis of breast cancer, 71 patients (69.6%) received adjuvant treatment. The majority were treated with adjuvant chemotherapy (n = 52, 51.0%) and/or adjuvant tamoxifen (n = 50, 49.0%). The most commonly used chemotherapeutic agents were cyclophosphamide, fluorouracil or methotrexate, alone or in combination. Only two patients (2.0%) received adjuvant trastuzumab treatment.
Previous therapies for advanced disease are summarised in Table 2 . Following the diagnosis of ABC, fulvestrant was used from the 1st to the 12th line of ABC therapy, and from the first to the fifth line of endocrine therapy. Overall, AIs were the most widely used class of first-and second-line endocrine therapy. By the third line, fulvestrant was the most commonly used endocrine agent ( Table 2 ). Trastuzumab was most commonly used in combination with other therapies and was used to treat a similar number of patients at each treatment stage.
response to fulvestrant treatment
Overall, 43 patients (42.2%) experienced CB with fulvestrant treatment ( Figure 2 ). Of these 43, five received trastuzumab treatment concurrently with fulvestrant and all five experienced SD ‡6 months. The combination of trastuzumab and fulvestrant was started simultaneously in three patients; in one patient, fulvestrant was added to trastuzumab monotherapy on progression; and in one patient, trastuzumab was added to fulvestrant monotherapy on progression. Four of five of the combination patients had received prior trastuzumab treatment, either alone or with chemotherapy. Three of the four had achieved PR or SD ‡6 months on their prior trastuzumab regimen.
In patients treated with fulvestrant alone, CB was noted up to the fourth line of endocrine therapy ( Figure 3A ) and up to the seventh line of overall therapy for ABC ( Figure 3B ). Median duration of treatment among patients gaining CB was 14.5 months (range 6-44).
In patients with visceral involvement (n = 63), the CB rate was 39.7% (Table 3) , similar to the CB rate of 46.2% in patients without visceral involvement (n = 39). Amongst ERpositive patients (n = 94), the CB rate was 44.7%. Rates of CB were comparable between ER-positive/PgR-positive patients and ER-positive/PgR-negative patients (Table 3) .
CB rates were similar regardless of which types of prior ABC treatments patients had received (Figure 4) . Of the 87 patients who received a prior endocrine treatment for ABC, most (n = 70) had previously demonstrated CB (CR, PR or SD ‡6 months). Half of these (n = 35) gained CB with fulvestrant. In addition, two patients who did not previously gain CB on prior endocrine therapy had CB with fulvestrant (one PR, one SD ‡6 months). Overall, patients who received prior trastuzumab (n = 43) had a CB rate of 46.5%, compared with 39.0% in those who had not received trastuzumab (n = 59). Approximately threequarters of those who received prior trastuzumab treatment (32/43, 74.4%) gained CB from it before progressing, and half of these (n = 16) went on to demonstrate CB with fulvestrant. Of the remaining 11, nine did not respond With regard to response to their last endocrine treatment, 39 patients (38.2%) gained no CB. Of these, 10 (25.6%) who subsequently received fulvestrant gained CB (1 PR, 9 SD ‡6 months). In total, 45/102 (44.1%) patients gained CB on their last endocrine treatment. Among these, 25 (55.5%) gained CB with fulvestrant; four of these achieved PR. Among the remaining patients (n = 18, 17.6%) whose CB status was unknown, or who had received no previous endocrine therapy, eight (44.4%) achieved CB with fulvestrant (one CR, three PR and four SD ‡6 months). All AEs were mild to moderate, with the exception of one case of severe restlessness, and were reported in 22 patients receiving fulvestrant (21.6%). One patient withdrew from treatment after a deep vein thrombosis. The most commonly reported AEs were dyspnoea (n = 5), nausea (n = 4), injectionsite pain (n = 4), musculoskeletal pain (n = 3) and headache (n = 3).
discussion
Endocrine therapies are generally better tolerated than chemotherapy and, for those in whom they are effective, provide a longer duration of control. Thus, endocrine therapy is an important option for patients with hormone receptorpositive ABC. Therefore, the possibility of treating HER2-positive disease with endocrine therapy represents a clinically significant goal. Current options include chemotherapy and trastuzumab, but chemotherapy may not always be necessary in ER-positive/HER2-positive disease [28] and, although trastuzumab is generally effective, it is less useful in certain patients, such as those with cardiac dysfunction. Novel treatment strategies, such as AIs or tamoxifen in combination with biological therapies, are also under investigation [29] . The current study demonstrates that the CB rate for fulvestrant is more than 40%, with an objective response (OR) rate of 9%, in patients with hormone receptor-positive, HER2-positive disease. By comparison, an early trial of trastuzumab in original article Annals of Oncology women with HER2-positive ABC (n = 222) showed on independent review an OR rate of 15.3% (8 patients with CR and 26 PR) [30] , while 62 patients had SD, giving a CB rate of 43.2%. Only 22% of treated patients were progression free at 6 months. Median time to progression was 3.1 months (range 0 to >28) [30] , compared with 8.1 months (range 1-44) in the present study. Patients in both studies were extensively pretreated (68% of trastuzumab study patients and 53% of fulvestrant patients received ‡2 prior chemotherapy treatments), with one-third having metastases at ‡3 sites (trastuzumab 36%; fulvestrant 33%) and around two-thirds having visceral involvement (trastuzumab 72%; fulvestrant 62%). In the current study, fulvestrant demonstrated a CB rate of 39.7% in HER2-positive patients with visceral disease, a population traditionally considered less responsive to endocrine therapy. The activity of fulvestrant appeared to be independent of PgR status. Fulvestrant may, therefore, provide an additional treatment option for HER2-positive patients with ABC. The retrospective nature of this analysis and the heterogeneous nature of the patients are limitations of this study. Nevertheless, assuming that 75% of ABC cases are ER positive [31] and that approximately 10% of these cases are also HER2 positive [5] , approximately 1400 patients with ABC would need to be assembled in a prospective study in order to obtain the number of ER-positive/HER2-positive patients included in this analysis. Due to the large sample population required, in practice, a prospective study of this nature may never occur. A further limitation is that response criteria were not uniform among centres and bias may have been introduced in some way. Despite these limitations, clinical experience data using a varied population of patients, such as those described here, reflect 'reallife' usage of fulvestrant in a range of cases that could be expected to arise in the clinic and, as such, the results are relevant to the clinical situation. Since CB rates obtained from clinical experience scenarios are often lower than those reported from well-controlled trials with a homogeneous population, the results from this study are encouraging. The CB rate in this study is similar to that seen in recent fulvestrant trials [10, 11, 32, 33] and in previous clinical experience reports [16, 34, 35] . Furthermore, in patients who gain CB, the responses are durable, thus delaying the requirement for toxic and/or expensive chemotherapeutic treatments with or without trastuzumab in these patients. In this study, fulvestrant as 2nd-through 12th-line therapy resulted in a CB rate of 25.6% in patients with hormone-resistant tumours. In addition, fulvestrant as 1st-through 11th-line therapy resulted in CB in at least 50% of hormone-sensitive patients, presenting a very attractive option for patients without immediately life-threatening disease.
We are unaware of any other pool of HER2-positive patients treated by endocrine means with which to compare these data.
It should be noted that AE reporting in this analysis was less stringent than in prospective trials. Nevertheless, the tolerability profile of fulvestrant was similar to that seen in previous trials [36] , with most AEs being mild to moderate.
If fulvestrant is seen as a reasonable option in HER2-positive disease, the next challenge is to define where it fits with existing treatments. Fulvestrant clearly retains activity in HER2-positive patients previously treated with trastuzumab (CB rate 46.5%) and also in some trastuzumab-resistant patients (2/9 patients, CB rate 22.2%). This makes it a valuable addition to the therapeutic armamentarium for these patients. Fulvestrant may also provide a useful option for patients who cannot tolerate trastuzumab or chemotherapy.
In addition, the use of combination therapy to disrupt both pathways may provide a novel therapeutic approach to delay or overcome the development of endocrine-resistant disease [37, 38] . The number of patients in this study who received fulvestrant plus trastuzumab was small. Nevertheless, the fact that all five showed CB, plus the fact that fulvestrant was effective in some patients who had previously progressed on trastuzumab or who were trastuzumab resistant, raises the possibility that fulvestrant and trastuzumab may each target a different proportion of HER2-positive tumours and may therefore have additive effects. Currently, the median duration of CB for the five patients treated with fulvestrant plus trastuzumab stands at 13 months (range 8-16), with treatment ongoing in one patient, compared with 14.5 months for all patients who gained CB. Clearly, further investigation would be required to determine whether there is any advantage in prescribing both treatments concurrently. A randomised phase II trial is underway to assess the efficacy of fulvestrant alone, trastuzumab alone, or the combination in postmenopausal women with HER2-positive/ hormone receptor-positive ABC. Nevertheless, the results will not be available for some time [39] .
It is possible that the unique mechanism of action of fulvestrant may make it particularly well suited to combination therapy with other novel targeted treatments. Indeed, several trials are planned or currently in progress. Combinations of fulvestrant plus gefitinib (an EGFR tyrosine kinase inhibitor) and anastrozole plus gefitinib are currently being compared with each other as first-or second line-therapy in postmenopausal women with hormone receptor-positive ABC. The combination of fulvestrant and tipifarnib (a farnesyltransferase inhibitor) demonstrated CB in 42.9% of patients [40] . The combination of bevacizumab (an antivascular endothelial growth factor antibody) with either fulvestrant or anastrozole will be examined in postmenopausal women with hormone-dependent metastatic breast cancer in a forthcoming clinical trial, in which HER2-positive patients will also be given trastuzumab [41] . The combination of fulvestrant and lapatinib (a dual kinase inhibitor) will also be assessed [42] .
Finally, although fulvestrant 250 mg/month appears active in ABC patients with HER2-positive tumours, reduction in ER expression is known to be incomplete with this approved dose. A high-dose regimen of fulvestrant (500 mg/month) is under investigation and may offer greater antitumour activity by achieving almost 100% reduction in ER expression and a concomitant reduction in ER/growth factor receptor pathway cross-talk [43] [44] [45] . It will be interesting to see how high-dose fulvestrant performs in HER2-positive patients.
In summary, the data reported here support the use of fulvestrant 250 mg/month as an option in HER2-positive, hormone receptor-positive ABC and provide evidence that such patients can be treated by endocrine means. Furthermore, the concept of employing drugs with a novel mode of action, alone and in combination with other therapies, in order to 
